They found that the FDA approved 85 (95%) of the drugs before the EMA, with the latter clocking up a median delay of 241 (150-370) days. But while the figures may sound stark, they come as no ...
Axatilimab has gained FDA approval in 9 mg and 22 mg vials, expanding treatment options for patients with chronic GVHD after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback